Fulltext

A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?

Nimdet K 1 , Chaiyakunapruk N 2 , Vichansavakul K 1 , Ngorsuraches S 1

Affiliations 

  • 1 Faculty of Pharmaceutical Sciences, Prince Songkla University, Hatyai, Thailand
  • 2 School of Pharmacy, Monash University Malaysia, Selangor, Malaysia; Center of Pharmaceutical Outcomes Research (CPOR), Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand; School of Pharmacy, University of Wisconsin, Madison, United States of America; School of Population Health, University of Queensland, Brisbane, Australia
PLoS One, 2015;10(4):e0122760.
PMID: 25855971 DOI: 10.1371/journal.pone.0122760

Abstract

A number of studies have been conducted to estimate willingness to pay (WTP) per quality-adjusted life years (QALY) in patients or general population for various diseases. However, there has not been any systematic review summarizing the relationship between WTP per QALY and cost-effectiveness (CE) threshold based on World Health Organization (WHO) recommendation.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications